Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association between the TP53BP1 rs2602141 A/C Polymorphism and Cancer Risk: A Systematic Review and Meta-Analysis

  • Liu, Lei (Department of Ophthalmology, The First Affiliated Hospital, China Medical University) ;
  • Zhang, Dong (Department of General Surgery, the Fourth People's Hospital of Shenyang) ;
  • Jiao, Jing-Hua (Department of Anesthesiology, Fengtian Hospital, Shenyang Medical College) ;
  • Wang, Yu (Department of Development and Planning Office, School of Public Health, China Medical University) ;
  • Wu, Jing-Yang (Department of Ophthalmology, The First Affiliated Hospital, China Medical University) ;
  • Huang, De-Sheng (Department of Epidemiology, School of Public Health, China Medical University)
  • Published : 2014.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The p53-binding protein 1 (TP53BP1) gene may be involved in the development of cancer through disrupting DNA repair. However, investigation of associations between TP53BP1 rs2602141 A/C polymorphism and cancer have yielded contradictory and inconclusive outcomes. We therefore performed a meta-analysis to evaluate the association between the TP53BP1 rs2602141 A/C polymorphism and cancer susceptibility. Materials and Methods: Published literature from PubMed, Medline, the Cochrane Library, EMbase, Web of Science, Google (scholar), CBMDisc, Chongqing VIP database, and CNKI database were retrieved. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed or random-effects models. Publication bias was estimated using funnel plots, Begg's and Egger's test. Results: A total of seven studies (3,018 cases and 5,548 controls) were included in the meta-analysis. Our results showed that the genotype distribution of TP53BP1 rs2602141 A/C was not associated with cancer risk overall. However, on subgroup analysis, we found that TP53BP1 rs2602141 A/C was associated with cancer risk within an allele model (A vs C, OR=1.14, 95%CI: 1.01-1.29) and a codominant model (AA vs CC, OR=1.36, 95%CI: 1.06-1.74) in Asians rather than in Caucasians. Subgroup analysis by cancer type, genotype, and with or without adjustment for controls showed no significant association. Conclusions: The findings suggested an association between rs2602141 A/C polymorphism in TP53BP1 gene and increased risk of cancer in Asians.

Keywords

References

  1. Camargo MC, Mera R, Correa P, et al (2006). Interleukin-1 beta and interleukin-1 receptor antagonistgene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 1674-87. https://doi.org/10.1158/1055-9965.EPI-06-0189
  2. Chen K, Hu Z, Wang LE, et al (2007). Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res, 13, 4300-5. https://doi.org/10.1158/1078-0432.CCR-07-0469
  3. DerSimonian R, Kacker R (2007). Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials, 28, 105-14. https://doi.org/10.1016/j.cct.2006.04.004
  4. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  5. DiTullio RA Jr, Mochan TA, Venere M, et al (2002). P53BP 1 functions in an ATM dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol, 4, 998-1002. https://doi.org/10.1038/ncb892
  6. Egger M, Davey SG, Schneider M, et al (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  7. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of world wide burden of cancer in 2008 : GLOBO CAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  8. Frank B, Hemminki K, Bermejo JL, et al (2005). TP53-binding protein variants and breast cancer risk: a case-control study. Breast Cancer Res, 7, 502-5. https://doi.org/10.1186/bcr1038
  9. Gao LB, Pan XM, Li LJ, et al (2011). RAD 51135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat, 125, 827-35. https://doi.org/10.1007/s10549-010-0995-8
  10. He C, Nan H, Qureshi AA, Han J (2010). Genetic variants in the 53BP1 gene and skin cancer risk. J Invest Dermatol, 130, 2850-3. https://doi.org/10.1038/jid.2010.227
  11. Liu GY, Jiang DK, Shen SQ, Yu L (2011). MDM2 SNP309T.>G polymorphism with hepatocellular carcinoma risk: a metaanalysis. Arch Med Res, 42, 149-55. https://doi.org/10.1016/j.arcmed.2011.02.002
  12. Ma H, Hu Z, Zhai X, et al (2006). Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis, 27, 766-71.
  13. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  14. Miwa S, Tome Y, Yano S, et al (2013). Single cell time-lapse imaging of focus formation by the DNA damage-response protein 53BP1 after UVC irradiation of human pancreatic cancer cells. Anticancer Res, 33, 1373-7.
  15. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 1000097. https://doi.org/10.1371/journal.pmed.1000097
  16. Naidu R, Har YC, Taib NA (2011). Genetic polymorphisms of TP53-binding protein 1 (TP53BP1) gene and association with breast cancer risk. APMIS, 119, 460-7. https://doi.org/10.1111/j.1600-0463.2011.02753.x
  17. Rappold I, Iwabuchi K, Date T, Chen J (2001). Tumor suppress or p53 binding protein1 (53BP1) is involved in DNA damagesignaling pathways. J Cell Biol, 153, 613-20. https://doi.org/10.1083/jcb.153.3.613
  18. Rauch T, Zhong X, Pfeifer GP, Xu X (2005). 53BP1 is a Positive Regulator of the BRCA1 Promoter. Cell Cycle, 4, 1078-83.
  19. Rudd MF, Webb EL, Matakidou A, et al (2006). Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res, 16, 693-701. https://doi.org/10.1101/gr.5120106
  20. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD (2000). p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol, 151, 1381-90. https://doi.org/10.1083/jcb.151.7.1381
  21. Truong T, Sauter W, Mc Kay JD, et al (2010). International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis, 31, 625-33. https://doi.org/10.1093/carcin/bgq001
  22. Wang B, Matsuoka S, Carpenter PB, Elledge SJ (2002). 53BP1, a mediator of the DNA damage checkpoint. Science, 298, 1435-8. https://doi.org/10.1126/science.1076182
  23. Weng Y, Lu L, Yuan G, et al (2012). p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. PLoS One, 7, 45820. https://doi.org/10.1371/journal.pone.0045820
  24. Williams RS, Green R, Glover JN (2001). Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol, 8, 838-42. https://doi.org/10.1038/nsb1001-838
  25. Zhang H, Hao S, Zhao J, et al (2013). Common Genetic Variants in 53BP1 Associated with Non-small Cell Lung Cancer Risk in Han Chinese. Arch Med Res, 45, 84-9.
  26. Zhao L, Zhao X, Wu X, Tang W (2013). Association of p53 Arg72Pro polymorphism with esophageal cancer: a meta-analysis based on 14 case-control studies. Genet Test Mol Biomarkers, 17, 721-6. https://doi.org/10.1089/gtmb.2013.0103

Cited by

  1. DOX-MTX-NPs Augment p53 mRNA Expression in OSCC Model in Rat: Effects of IV and Oral Routes vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8377
  2. No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5663